Regulation of signaling pathways by Ampelopsin (Dihydromyricetin) in different cancers: exploring the highways and byways less travelled

Sundas Fayyaz; Muhammad Zahid Qureshi; Saleh S Alhewairini; Seda Avnioglu; Rukset Attar; Uteuliyev Yerzhan Sabitaliyevich; Aleksandra Buha; Hina Salahuddin; Aima Adylova; Fatima Tahir; Edyta Pawlak-Adamska

doi:10.14715/cmb/2019.65.7.4

Issue

Vol. 65 No. 7: Issue 7

Issue Published : October 14, 2019

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Regulation of signaling pathways by Ampelopsin (Dihydromyricetin) in different cancers: exploring the highways and byways less travelled

https://doi.org/10.14715/cmb/2019.65.7.4

Sundas Fayyaz

Department of Biochemistry, Rashid Latif Medical College (RLMC), Lahore, Pakistan

Muhammad Zahid Qureshi

Department of Plant Production and Protection, College of Agriculture and Veterinary Medicine, Qassim University, Al-Qassim, Saudi Arabia

Saleh S Alhewairini

Department of Plant Production and Protection, College of Agriculture and Veterinary Medicine, Qassim University, Al-Qassim, Saudi Arabia

Seda Avnioglu

Department of Anatomy, Faculty of Medicine, Alanya Alaaddin Keykubat University, Antalya, Turkey

Rukset Attar

Department of Obstetrics and Gynecology, Yeditepe University, Ataşehir/ć°stanbul 34755, Turkey

Uteuliyev Yerzhan Sabitaliyevich

Department of Postgraduate Education and Research, Kazakhstan Medical University KSPH, Almaty, Kazakhstan

Aleksandra Buha

Department of Toxicology "Akademik Danilo Soldatovic", University of Belgrade-Faculty of Pharmacy, Serbia

Hina Salahuddin

Department of Zoology, University of Okara, Pakistan

Aima Adylova

Department of Postgraduate Education and Research, Kazakhstan Medical University KSPH, Almaty, Kazakhstan

Fatima Tahir

Department of Biochemistry, Rashid Latif Medical College (RLMC), Lahore, Pakistan

Edyta Pawlak-Adamska

Department of Experimental Therapy, Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland

Corresponding Author(s) : Sundas Fayyaz

Sundas.khan23@yahoo.com

Cellular and Molecular Biology, Vol. 65 No. 7: Issue 7
Article Published : September 30, 2019

Abstract

Ampelopsin or Dihydromyricetin is gradually emerging as a high-quality natural product because of its ability to modulate wide-ranging signaling pathways. Ampelopsin (Dihydromyricetin) has been reported to effectively modulate growth factor receptor (VEGFR2 and PDGFRÎ²) mediated signaling, TRAIL/TRAIL-R pathway, JAK/STAT and mTOR-driven signaling in different cancers. Ampelopsin (Dihydromyricetin) has also been shown to exert inhibitory effects on the versatile regulators which trigger EMT (Epithelial-to-Mesenchymal Transition). Findings obtained from in-vitro studies are encouraging and there is a need to comprehensively analyze how Ampelopsin (Dihydromyricetin) inhibits tumor growth in different cancer models. Better knowledge of efficacy of Ampelopsin (Dihydromyricetin) in tumor bearing mice will be helpful in maximizing its translational potential.

Keywords

Ampelopsin Dihydromyricetin Cancer Apoptosis Therapy Signaling.

Fayyaz, S., Qureshi, M. Z., Alhewairini, S. S., Avnioglu, S., Attar, R., Sabitaliyevich, U. Y., Buha, A., Salahuddin, H., Adylova, A., Tahir, F., & Pawlak-Adamska, E. (2019). Regulation of signaling pathways by Ampelopsin (Dihydromyricetin) in different cancers: exploring the highways and byways less travelled. Cellular and Molecular Biology, 65(7), 15–20. https://doi.org/10.14715/cmb/2019.65.7.4